Sanofi has inked a licensing deal with Scribe Therapeutics, co-founded by CRISPR pioneer Jennifer Doudna, to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,